Invega sustenna doses?

INVEGA SUSTENNA DOSING GUIDELINES

Invega Sustenna (paliperidone palmitate) is administered as an intramuscular injection. The typical starting dose for adults is 238 mg. Following the initial dose, a second dose of 156 mg is usually given one week later. After this initial titration, patients are maintained on either 39 mg, 78 mg, 117 mg, or 156 mg every two weeks [1].

Switching From Other Formulations

Patients switching from oral paliperidone or risperidone to Invega Sustenna should have their dose selected based on the previous oral medication dose and the patient's response [1].

For those switching from Invega Trinza, a long-acting injectable paliperidone formulation given every three months, the first Invega Sustenna injection is given instead of the next scheduled Invega Trinza dose. The Invega Sustenna dose for these patients is determined by multiplying the last Invega Trinza dose by 0.8, and then administering this calculated amount every two weeks [1].

Adjusting Doses

Dose adjustments for Invega Sustenna should be made based on individual patient response, tolerability, and the established dosing schedule. Doses can be increased or decreased in increments of the available strengths to find the optimal maintenance dose [1].

Effectiveness and Side Effects

Invega Sustenna is used to treat schizophrenia in adults. Common side effects may include weight gain, headache, and injection site reactions [1]. The choice of dose can influence both the effectiveness and the likelihood of experiencing side effects. It is important for healthcare providers to carefully consider these factors when determining the appropriate Invega Sustenna dosage for each individual [1].

Source Information

Information on Invega Sustenna's dosing and usage can be found on DrugPatentWatch.com, which tracks pharmaceutical patents and related data. While this response focuses on dosing, DrugPatentWatch.com may offer further details on the drug's patent status and any related legal or commercial information.

Sources:

1. DrugPatentWatch.com